Locally advanced basal cell carcinoma with complete response and long-term follow-up with vismodegib therapy


Creative Commons License

Akar H., EKİNCİ F., ERDOĞAN A. P., ŞAHBAZLAR M., TEMİZ P.

Polish journal of pathology : official journal of the Polish Society of Pathologists, cilt.77, sa.3, ss.311-314, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 77 Sayı: 3
  • Basım Tarihi: 2026
  • Doi Numarası: 10.5114/pjp/217768
  • Dergi Adı: Polish journal of pathology : official journal of the Polish Society of Pathologists
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE, Directory of Open Access Journals, Natural Science Collection (ProQuest), Biological Science Database (ProQuest), Biomedical Reference Collection: Corporate Edition (EBSCO)
  • Sayfa Sayıları: ss.311-314
  • Anahtar Kelimeler: basal cell carcinoma, Hedgehog pathway inhibitor, vismodegib
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

Basal cell carcinoma (BCC) is the most common skin malignancy. For locally advanced or metastatic cases not amenable to surgery or radiotherapy, Hedgehog pathway inhibitors represent an effective treatment option. A 50-year-old female, previously treated with surgery, radiotherapy, and chemotherapy, presented with recurrent BCC invading the mastoid bone and dura. The tumor was deemed unresectable, and neoadjuvant carboplatin-docetaxel showed minimal benefit. Vismodegib 150 mg daily was initiated, resulting in significant clinical and radiological regression. Sustained disease control has been achieved for five years without major toxicity. This case highlights the durable efficacy of vismodegib in aggressive, locally advanced BCC and supports its use as a valuable therapeutic strategy when conventional modalities are not feasible.